期刊
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
卷 63, 期 -, 页码 207-222出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neubiorev.2016.01.001
关键词
IGF-1; Insulin-like growth factor 1; Neurotrophic factors; Central nervous system disorders; CNS development; Neurodevelopmental disorders; ASD; Autism spectrum disorder; Fragile X syndrome; Phelan-McDermid syndrome; Rett syndrome
资金
- Beatrice and Samuel A. Seaver Foundation
- Autism Science Foundation
- National Institute of Mental Health [MH100276-01]
- National Institute of Neurological Disorders and Stroke [U54 NS092090-01]
Central nervous system (CNS) development is a finely tuned process that relies on multiple factors and intricate pathways to ensure proper neuronal differentiation, maturation, and connectivity. Disruption of this process can cause significant impairments in CNS functioning and lead to debilitating disorders that impact motor and language skills, behavior, and cognitive functioning. Recent studies focused on understanding the underlying cellular mechanisms of neurodevelopmental disorders have identified a crucial role for insulin-like growth factor-1 (IGF-1) in normal CNS development. Work in model systems has demonstrated rescue of pathophysiological and behavioral abnormalities when IGF-1 is administered, and several clinical studies have shown promise of efficacy in disorders of the CNS, including autism spectrum disorder (ASD). In this review, we explore the molecular pathways and downstream effects of IGF-1 and summarize the results of completed and ongoing pre-clinical and clinical trials using IGF-1 as a pharmacologic intervention in various CNS disorders. This aim of this review is to provide evidence for the potential of IGF-1 as a treatment for neurodevelopmental disorders and ASD. (C) 2016 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据